NASDAQ:VTRS

Viatris Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy VTRS

*Your capital is at risk

$16.39

+0.120 (+0.738%)

At Close: Jul 13, 2026

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

04:43pm, Monday, 05'th Aug 2024

Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and devel

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

12:41pm, Monday, 05'th Aug 2024

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

10:21am, Monday, 05'th Aug 2024

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu

Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline

11:05am, Thursday, 01'st Aug 2024

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Surprisingly Underrated Stocks to Buy Right Now

12:25pm, Friday, 26'th Jul 2024

AstraZeneca is a healthcare giant trading at a discount. There's more to the story with Pfizer than its COVID woes and looming patent cliff.

Viatris Inc (VTRS:NAS) Company Profile: Analytics, Extensive Financial Metrics, and Benchmark Against Averages and Top Companies Within its Industry

12:00pm, Friday, 26'th Jul 2024

Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Viatris Inc (VTRS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry" company profile fr

Idorsia announces financial results for the first half 2024

01:00am, Thursday, 25'th Jul 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024.

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

01:21pm, Wednesday, 10'th Jul 2024

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture

08:30am, Wednesday, 03'rd Jul 2024

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH , July 3, 2024 /PRNewswir

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

08:17am, Tuesday, 02'nd Jul 2024

Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.

U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation

07:30am, Tuesday, 02'nd Jul 2024

PITTSBURGH , July 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers My

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by